This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Inflectra® (infliximab) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Biosimilars overview

What is a biosimilar

The future of biosimilars

Considerations for biologic switching

Inflectra/CT-P13* has robust clinical data for switching patients from Remicade®† to Inflectra/CT- P13*.1-10

EU and UK guidance supports switching from reference biologics to a biosimilar in appropriate patients.11-14

Decisions regarding treatment choice or physician-mediated switching must be a clinical decision made by a treating physician on an individual patient basis, supported by scientific evidence, ensuring safety of patients is not compromised, and with patient awareness.

Watch the video to discover more about the potential benefits of switching to a biosimilar:

*CT-P13 is marketed under different brand names including Inflectra and REMSIMA®.
†Remicade® is a registered trademark of MSD.

Explore more

Rheumatoid arthritis dosing

Learn about the dosing and administration of Inflectra in patients with rheumatoid arthritis

Find out more

Rheumatoid arthritis safety

Learn about the safety profile of Inflectra in patients with rheumatoid arthritis

Learn more
References
  1. Jørgensen KK, et al. Lancet 2017. 389:2304–2316
  2. Kim YH, et al. Abstract 101, AOCC 2017.
  3. Kim YH, et al. Abstract DOP061. Ecco 2017. J Crohns Colitis. 2017. Supp I.
  4. Kim YH, et al. Abstract LB04, UEGW 2017. United European Gastroenterol J. 2017. 5: 1139-40.
  5. ClinicalTrials.gov. NCT02096861. [online][viewed: February 2021]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02096861?term=CT-P13.
  6. Abstracts of ECCO 2017. J Crohns Colitis 2017; 11/Supp 1 [Alfonso J, et al. Ametzazurra A, et al. P503. Choe YH, et al. P500. Curdia Goncalves T, et al. P472. Fiorino G, et al. P605. Gecse KB, et al. P331. Gonzalez A., et al. P508. Han S, et al. P582. Juan G, et al. P632. Kaniewska M, et al. P425. Kolar M, et al. P532. Lovasz, et al. P592. Molnar, et al. P675. Mortier K, et al. P333. Eberl A, et al. P639. Huoponen S, et al. P685. Smits L, et al. P663. Strik A, et al. P665. Gompertz M, et al. P679. Guerrero Puente LN, et al. P545. Rodriguez Glez GE, et al. P629. St. Clair Jones A, et al. P527. Plevris N, et al. P586. Nugent S, et al. P430. Soret PA, et al. P471. Choe YH, et al. P487. Kamg B, et al. P542. Sladek M, et al. P661. Fiorino G, et al. P633.]
  7. Abstracts of ECCO 2016. J Crohns Colitis 2016. 10/Supp 1 [Bortilk M, et al. P495. Carvalho L, et al. P327. Hamanaka S, et al. P329. Kaniewska M, Rydzewska G. P645. Zagorowicz E, et al. P513. Kolar M, et al. DOP032. Diaz Hernandez L, et al. P449. Guerra Veloz MF, et al. P452. Guerra Veloz MF, et al. P600. Muhammed R, et al. P382. Sieczkowska J, et al. P530. Turk N, et al. P577.]
  8. Abstracts of BSG 2016. Gut 2016;7/Supp1 [Ala K, et al. PTU-059. Bennett KJ, et al. PWE-017. Chung L, et al. OC-038. RahmanyS, et al. PTU-073.]
  9. RazanskaiteV, et al. J Crohns Colitis. 2017. 11(6):690-6.
  10. Smits LJ, et al. J Crohns Colitis. 2016. 10:1287-93.
  11. Danese S, et al. J Crohns Colitis. 2017. 11(1):26-34.
  12. NICE Guidance; Technology appraisal guidance [TA329]. [online][viewed: February 2021]. Available from: https://www.nice.org.uk/guidance/ta329.
  13. BSG Guidance on the Use of Biosimilar Infliximab CT-P13 in IBD. [online]. [viewed: February 2021].Available from: https://www.bsg.org.uk/resource/bsg-guidance-on-the-use-of-biosimilar-infliximab-ct-p13-in-ibd.html
  14. British Society for Rheumatology Position Statement on Biosimilar Medicines [online]. 2017[viewed: February 2021]. Available from: https://www.nras.org.uk/data/files/revised_bsr_biosimilars_position_statement_jan_2017.pdf
PP-IFA-GBR-0406. March 2021

Quick Links

  • Inflammatory bowel disease

  • Infliximab mechanism of action

  • Support & Resources

Learn about the evidence supporting the use of Inflectra in patients with rheumatoid arthritis.

Find out more

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No